Found: 11
Select item for more details and to access through your institution.
Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
- Published in:
- Cancer Research & Treatment, 2024, v. 56, n. 1, p. 162, doi. 10.4143/crt.2023.330
- By:
- Publication type:
- Article
Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study.
- Published in:
- Cancer Research & Treatment, 2021, v. 53, n. 3, p. 881, doi. 10.4143/crt.2020.1008
- By:
- Publication type:
- Article
Open Access Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
- Published in:
- Cancer Research & Treatment, 2018, v. 50, n. 2, p. 488, doi. 10.4143/crt.2016.584
- By:
- Publication type:
- Article
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea.
- Published in:
- Cancer Research & Treatment, 2016, v. 48, n. 4, p. 1382, doi. 10.4143/crt.2015.423
- By:
- Publication type:
- Article
Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment.
- Published in:
- Turkish Journal of Hematology, 2019, v. 36, n. 2, p. 106, doi. 10.4274/tjh.galenos.2019.2019.0306
- By:
- Publication type:
- Article
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Analysis of Efficacy and Predictive Factors for Treatment Response of Thalidomide-Containing Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Prior Chemotherapy Including Bortezomib and Lenalidomide.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e69, doi. 10.1016/j.clml.2017.03.125
- By:
- Publication type:
- Article
Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0271-4
- By:
- Publication type:
- Article
Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 7, n. 1, p. 27, doi. 10.3892/mco.2017.1272
- By:
- Publication type:
- Article